Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease
Conditions
Brief summary
The purpose of this study is to provide continued access to TPIP for participants who have successfully completed the open-label extension (OLE) studies of INS1009-203 for PAH or INS1009-212 for PH-ILD.
Detailed description
Participants will receive TPIP 80 micrograms (μg), 160 μg, or 320 μg, inhalation single-dose capsules, orally, once daily (QD).
Interventions
Treprostinil Palmitil Inhalation Powder
Sponsors
Insmed Incorporated
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* The participant is ineligible for or cannot be treated satisfactorily with alternative commercially available therapy for PAH or PH-ILD. * Participant provides their informed consent to participate as per local requirements. * Participant must have successfully completed the OLE INS1009-203 or INS1009-212 studies. * Based on the treating physician's judgement on participant's medical history and an evaluation of the overall risk-benefit profile, the participant will be determined to be suitable for continued TPIP treatment within this program. * Requests for the post-OLE INS1009-203 and INS1009-212 TPIP studies must originate from the investigators of INS1009-203 and INS1009-212 TPIP studies, respectively. * Female participants must be postmenopausal (defined as no menses for 12 months without an alternative medical cause), surgically sterile, or using highly effective contraception (failure rate \<1% per year when used consistently and correctly) from Day 1 to at least 90 days after the last dose. * Male participants with female partners must adhere to contraception requirements to avoid potential exposure to the embryo/fetus based on the partner's reproductive status. For partners of childbearing potential, effective contraception must be used from Day 1 to at least 90 days after the last dose.
Exclusion criteria
• No specific
Contacts
CONTACTInsmed Medical Information
Outcome results
None listed